Epigenic Therapeutics, a Shanghai-based biotechnology company dedicated to developing gene modulation therapy to treat prevalent diseases, has raised $32 million in Series A funding. The round was co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital.
The company plans to use the funds to support the preclinical development and early clinical validation of two leading programs, the discovery of future pipelines, the expansion of the leadership team, and continued investments in its core technology platforms. Epigenic Therapeutics is led by CEO Bob Zhang. The company was founded in 2021 with a mission to develop gene editing therapy that utilizes regulation of the epigenetic genome for a variety of diseases. The company has multiple product candidates in its pipeline, including treatments for metabolic, cardiovascular, viral hepatitis, ocular, and rare diseases.
Epigenic Therapeutics' proprietary technology platform, EPIREG™, uses artificial intelligence (AI) algorithms to explore and obtain an optimized CRISPR-Cas component to regulate target genes or govern the expression of one or multiple genes at once without changing the sequence of the DNA. The platform also combines a proprietary lipid nanoparticle (LNP) medicine delivery system that has been proven to deliver medicine to target cells and tissues ex vivo and in vivo in metabolic, cardiovascular, viral hepatitis, ocular, and rare disease models. The company's Series A funding will help it accelerate the development of its gene modulation therapy platform and bring new treatments to patients with prevalent diseases.
